According to the National Alliance on Mental Illness and the World Health Organization, depression affects 16 million Americans and 322 million people worldwide. Emerging evidence suggests that the COVID-19 pandemic is further exacerbating the prevalence of depression in the general population. With this trajectory, it is evident that more effective strategies are needed for therapeutics that address this critical public health issue.